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Abstract
Background—Influenza vaccination may provide a “back-boost” to antibodies against 
previously encountered strains. If the back-boost effect is common, this could allow more 
aggressive vaccine updates, as emerging variants would be expected to both elicit de-novo 
responses and boost pre-existing responses against recently circulating strains. Here we used the 
emergence of an antigenically novel A(H3N2) strain to determine whether an antigenically 
updated vaccine boosted antibodies against historical strains.
Methods—We performed hemagglutination-inhibition (HI) assays on pre- and post-vaccination 
sera from 124 children 5–17 years old who received 2015–2016 inactivated influenza vaccine, 
containing an antigenically updated A(H3N2) strain. We evaluated the mean fold increase in HI 
titer against both the 2015–2016 vaccine strain and representative strains from two prior antigenic 
clusters. Factors associated with post-vaccination titers against historical strains were evaluated 
using linear regression, adjusting for baseline titer.
Results—Geometric mean titers against each antigen examined increased significantly after 
vaccination (P <0.0001). Mean fold increase was 3.29 against the vaccine strain and 1.22–1.46 
against historical strains. Response to vaccine strain was associated with increased post-
vaccination titers against historical strains.
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Conclusions—A vaccine containing an antigenically novel A(H3N2) strain modestly boosted 
antibody responses against historical influenza strains in children.
Keywords
influenza; vaccine; pediatrics; back-boost
Introduction
Influenza viruses undergo continuous antigenic evolution that is punctuated by the periodic 
emergence of variants with substantial antigenic differences from previously circulating 
variants. As a result, influenza virus strains can be grouped into clusters of antigenically 
similar viruses, where new clusters are created during the expansion of a drift variant [1]. 
These antigenic drift variants can emerge unpredictably and sometimes suddenly, which 
complicates vaccine strain selection. Decisions regarding the recommended influenza 
vaccine composition start 6–7 months before the influenza season [2,3]. During this time an 
antigenically novel strain can emerge, creating a mismatch between vaccine and circulating 
strains and reducing vaccine effectiveness. Before the 2014–15 influenza season an antigenic 
cluster transition created a larger-than-usual mismatch between the circulating A(H3N2) 
strain and the vaccine strain, A/Texas/50/2012. This virus was antigenically similar to a 
majority of circulating A(H3N2) viruses in early 2014 [4]. However, increasing prevalence 
of antigenically drifted A(H3N2) viruses during the 2014–15 season resulted in poor 
A(H3N2)-specific vaccine effectiveness [5,6].
An individual’s repertoire of antibody responses is shaped by each influenza exposure event. 
It has been shown that pre-existing immunity as well as vaccine effectiveness can affect the 
response to vaccination [7,8]. However, there have been few studies examining how an 
influenza exposure can affect the pre-existing antibody repertoire. Recently, Fonville et al. 
demonstrated how exposure events alter the overall hemagglutination-inhibition (HI) 
antibody response by simultaneously visualizing antigenic distances among influenza strains 
and the magnitude of HI antibody responses to create an “antibody landscape” [9]. 
Intriguingly, they noted that both infection and vaccination boosted antibody responses 
against not only the vaccine or infecting strain, but also against historical influenza strains, 
resulting in a “back-boost” effect [9]. This study also noted that vaccination with an updated 
influenza vaccine in 1997 was capable of boosting responses against the previously 
circulating antigenic variant A/Wuhan/359/1995 to levels higher than those elicited by the 
homologous A/Nanchang/933/1995 vaccine [9].
The “back-boost” effect raises the possibility of employing a new vaccine strain selection 
process in which vaccines can be updated with emerging, antigenically novel strains, even 
when they do not yet predominate among circulating viruses. The antigenically advanced 
strain would be relied upon to elicit antibodies against the emerging antigenic variant while 
also boosting antibodies against historical strains, thus providing coverage against both 
“new” and “old” strains. The back-boost effect was initially identified in adults and relies on 
pre-existing influenza immunity; here we determined whether a similar back-boost could 
occur in children who have comparatively limited influenza exposure histories. The study 
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recruited children with and without a known prior infection with influenza A(H3N2) viruses, 
which allowed us to examine factors associated with a back-boost response.
Methods
Study population and serum collection
This study was carried out in fall 2015 before the North American 2015–2016 influenza 
season. Parents of children 5–17 years old were contacted by mail and telephone inviting 
their child to participate in a vaccine immune response study before they received their 
2015–2016 influenza vaccine. Participants were selected from children who 1) previously 
participated in similar influenza vaccine immune response studies in the previous two 
influenza seasons, or 2) lived in Marshfield, Wisconsin where annual studies of influenza 
vaccine effectiveness were conducted [10]. We restricted recruitment to this population 
because influenza vaccinations are captured using a validated vaccination registry [11] and 
medically attended influenza illnesses were prospectively identified and confirmed by RT-
PCR. All participants received the 2015–2016 trivalent inactivated influenza vaccine (IIV3) 
delivered intramuscularly, containing an A/Switzerland/9715293/2013-like A(H3N2) virus, 
and provided a serum sample before vaccination and 28 days after vaccination. Data on 
demographics and high-risk conditions were electronically extracted from the medical 
record.
Study procedures were approved by the Marshfield Clinic Institutional Review Board. 
Informed consent was obtained from the parents/guardians of all participants and assent was 
obtained from children aged ≥7 years.
Hemagglutination inhibition (HI) assay
HI assays were performed at the University of Wisconsin-Madison on pre-baseline and post-
vaccination serum samples as described by the World Health Organization [12]. Briefly, 1 
part serum was mixed with 3 parts receptor-destroying enzyme II (RDEII; Accurate 
Chemical, Westbury, NY) and incubated at 37°C for 18–20 hours to remove non-specific 
inhibitors of hemagglutination. RDEII was then inactivated by incubating the samples at 
56°C for 30 minutes. To remove non-specific antibodies 1 part packed guinea pig red blood 
cells (Innovative Research, Novi, MI) was mixed with 10 parts serum and incubated at room 
temperature for 1 hour, inverting every 15 minutes. The samples were then diluted to a total 
serum dilution factor of 1:10 with PBS and oseltamivir (final concentration 20nM; ApexBio, 
Houston, TX) and serial two-fold dilutions were mixed with 4 HA units of A(H3N2) viruses 
in a U-bottomed microtiter plate. The plates were incubated at room temperature for 30 
minutes, then 0.75% guinea pig red blood cells were added with a final oseltamivir 
concentration of 20nM. The samples were then incubated again for 30 minutes at room 
temperature. The reciprocal of the dilution at which no inhibition was observed was 
recorded as the HI antibody titer. If inhibition was not observed a serum dilution of 1:5 was 
recorded as a negative result to allow for statistical analysis. Samples were tested in 
duplicate with pre- and post-vaccination samples from the same participants tested at the 
same time. Wells with 4 HA units of virus and PBS were kept as positive and negative 
controls for hemagglutination.
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Antibody titers were determined against the following viruses: the 2015–2016 vaccine strain 
A/Switzerland/9715293/2013 (SW/13) (ATCC, Manassas, VA) belonging to the genetic 
clade 3C.3a; the 2014–2015 vaccine strain A/Texas/50/2012 (TX/12) (ATCC, Manassas, 
VA) belonging to clade 3C.1; the 2012–2013 vaccine strain A/Victoria/361/2011 (VI/11) 
(ATCC, Manassas, VA) belonging to clade 3C.1; and A/Wuhan/359/1995 (WU/95) (kindly 
provided by Dr. Yoshihiro Kawaoka) which represented an A(H3N2) antigenic cluster that 
circulated from 1995–1997, before the participants were born [13]. Viruses were grown in 
cell culture using MDCK-SIAT1 cells.
Statistical analyses
The primary outcome was geometric mean fold increase (MFI) in HI titers against TX/12; 
MFI was also assessed for VI/11, a virus from the same antigenic cluster as TX/12, and for 
WU/95, which is antigenically distinct from TX/12. An analysis of MFI was stratified based 
on baseline TX/12 HI titer <40 or ≥40 to account for potential differential antibody response 
due to baseline TX/12 HI titer. Seroprotection against the previous season vaccine strain, 
TX/12, was determined for two levels of protection, defined as the proportion with post 
vaccination HI titer ≥40, the titer level considered seroprotective for regulatory purposes; 
and ≥110, which has been suggested to correspond to 50% clinical protection in children 
[14,15].
Linear regression models with log2-transformed HI titers were used to identify factors 
associated with post-vaccination HI titer against viruses representing past A(H3N2) 
antigenic clusters, adjusting for baseline HI titers. Factors examined included SW/13 
(vaccine strain) MFI, age group (5–11 and 12–17 years), presence of a high-risk condition, 
vaccination group (any vs. no vaccination within the last 5 years), and A(H3N2) infection 
history within the last 5 years. High-risk conditions were defined by presence of a healthcare 
visit or hospitalization during the previous 12 months with ≥1 ICD-9 diagnosis codes for 
conditions associated with increased risk of influenza, as previously described [16,17]. 
Covariates associated with post-vaccination titer at P <0.05 in backwards elimination were 
included in the final linear regression model. Separate regression models were used to assess 
titers against each historical strain: TX/12, VI/11, and WU/95. Estimates of post-vaccination 
geometric mean titers (GMT) for each historical antigen were calculated and plotted 
adjusting for the baseline GMT for each antigen using “predicted marginal means” or “least-
squares means,” available in the R package lsmeans [18].
Logistic regression was used to identify predictors of post-vaccination seroprotection against 
TX/12. For this analysis, participants with baseline titers above the seroprotective level (≥40 
or ≥110) were excluded. The same covariates assessed in the linear regression model were 
examined in the logistic regression models.
All analyses were performed using R version 3.3.0 [19]. Figures were generated using 
GraphPad Prism 6 and R package ggplot2 [20].
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Results
Participant characteristics
There were 124 participants with paired sera from both baseline and post vaccination visits. 
The mean age was 12 years, and 54 (44%) were female. In the 2014–2015 (prior) season, 77 
(62%) received inactivated influenza vaccine (IIV), 13 (11%) received live attenuated 
influenza vaccine (LAIV), and 34 (27%) were unvaccinated; 22 (18%) had PCR-confirmed 
influenza A (H3N2) virus infection. At baseline, 95 (77%) had HI titer ≥40 against A/Texas/
50/2012 (TX/12), the strain in the prior season vaccine. There were no significant 
differences between participants who had baseline titers of either <40 or ≥40 against TX/12 
with regard to age group, sex, presence of high-risk medical conditions, prior (2014–2015) 
season vaccination history, or history of PCR-confirmed A(H3N2) influenza infection in 
2012–2013 (group 3C.1) or 2014–2015 (group 3C.2a) (Table 1).
Baseline and vaccine response to the vaccine strain SW/13
Baseline responses against the vaccine strain SW/13 could indicate prior exposure to that 
virus, which might affect back-boost responses. We found that participants with baseline HI 
titers ≥40 against TX/12 had higher baseline titers against the group 3C.3a A/Switzerland/
9715293/2013 (SW/13; 2015–2016 vaccine) strain than participants with baseline HI titers 
<40 against TX/12 (GMT 68 vs 18, P <0.001; Table 1). Participants with a PCR-confirmed 
A(H3N2) infection during the 2012–2013 season had a baseline GMT of 75 against SW/13 
(95% CI 36 – 153; Table 1). Participants with a PCR-confirmed A(H3N2) infection during 
the 2014–2015 season, during which SW/13-like viruses first circulated, had a baseline 
GMT of 60 (95% CI 44 – 83; Table 1). After vaccination, the unadjusted MFI against SW/13 
was 3.30 (95% CI 2.36 – 4.63) and 3.28 (95% CI 2.73 – 3.95) for those with baseline TX/12 
titer <40 and ≥40, respectively (Figure 1 and Table 2). Thus participants responded to 
vaccination with SW/13, although for most participants these responses were modest.
Baseline and vaccine response to viruses representing past A(H3N2) antigenic clusters
The central question of our study was whether vaccination with an updated A(H3N2) 
antigen provides a back-boost to recently circulating strains in children. The back-boost 
response generated by the SW/13 vaccine strain was evaluated against both the closely 
related TX/12 and VI/11 strains of recent vaccines and the distant WU/95.
Prior season vaccine strains TX/12 and VI/11—At baseline, all participant groups 
had mean baseline titers <40 against the previous vaccine strain A/Victoria/361/2011 (VI/
11), even those with baseline titers >40 against TX/12 (Table 1). Participants with a PCR-
confirmed A(H3N2) infection during the 2012–2013 or 2014–15 seasons had baseline 
GMTs of >40 against TX/12, but <40 against VI/11 (Table 1). If vaccination provided a 
back-boost against recent, “antigenically adjacent” viruses in our participants, we would 
expect to observe a significant increase in mean fold titers against VI/11 and TX/12. The 
unadjusted MFI in participants with baseline TX/12 titer <40 was 1.84 (95% CI 1.50 – 2.26) 
against TX/12 and 1.61 (95% CI 1.33 – 1.95) against VI/11 (Figure 1A and Table 2). 
Similarly, MFI in participants with baseline TX/12 HI titers ≥40 was 1.36 (95% CI 1.25 – 
1.48) against TX/12 and 1.37 (95% CI 1.25 – 1.51) against VI/11 (Figure 1B and Table 2). 
Florek et al. Page 5
Vaccine. Author manuscript; available in PMC 2019 January 29.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Thus we observed modest, but statistically significant, increases against both recent vaccine 
strains VI/11 and TX/12 after vaccination with the new antigenic variant SW/13.
Antigenically distant A/Wuhan/359/1995 (WU/95)—WU/95 circulated before the 
individuals in this cohort were born; we expect that participants would not have been 
exposed to this virus and would therefore not mount a back-boost response to it. Consistent 
with this expectation, all participants had low baseline titers against WU/95, though the 
baseline titer against this virus trended slightly higher in participants with baseline TX/12 
≥40 (GMT 9 vs. 18, respectively; Table 1). Participants with a PCR-confirmed A(H3N2) 
infection during the 2012–2013 season had a baseline GMT of 10 (95% CI 6 – 17; Table 1). 
Likewise, participants with a PCR-confirmed A(H3N2) infection during the 2014–2015 
season had a baseline GMT of 15 (95% CI 11 – 20; Table 1). In participants with baseline 
TX/12 HI titer <40, there was no significant difference in pre- and post-vaccination titers 
against WU/95 (P = 0.44; Figure 1A and Table 2), while participants with baseline TX/12 
titer ≥40 had a MFI of 1.24 (95% CI 1.13 – 1.35) against WU/95 (Figure 1B and Table 2).
Factors associated with responses to SW/13 and viruses representing past A(H3N2) 
antigenic clusters
To determine which factors influence the back-boost response, we examined multiple 
covariates in a regression model to measure their association with the back-boost responses 
to the recent antigenic clusters. We found baseline titer and SW/13 response to be associated 
with the back-boost in antibody titers against TX/12 and VI/11. Adjusting for baseline 
TX/12 titer, a 2-fold increase in SW/13 response from pre- to post-vaccination was 
associated with an average increase of 19% (95% CI 13% – 25%) in post-vaccination titer 
against TX/12 (Figure 2 and Table 3). For VI/11, a 2-fold increase in SW/13 response from 
pre- to post-vaccination was associated with an average increase in post-vaccination titer 
against VI/11 of 14% (95% CI 7% – 21%) adjusting for baseline VI/11 titer (Figure 2 and 
Table 3). For WU/95, a 2-fold increase in SW/13 response from pre- to post-vaccination was 
associated with an average increase in post-vaccination titer against WU/95 of 11% (95% CI 
5% – 17%) adjusting for baseline WU/95 titer (Figure 2 and Table 3). The regression models 
explained 73%, 74%, and 83% of the variability in post-vaccination titers against TX/12, 
V11, and WU/95, respectively. Age (Figure S1), high-risk condition, vaccination group, and 
infection status were examined but did not significantly impact post-vaccination titers 
against any viruses.
Factors associated with seroprotection against the previous season vaccine strain TX/12
Finally, because the goal of vaccination is to induce a protective level of antibodies, we 
determined whether back-boost effects could induce seroprotective antibody titers against 
the previous vaccine strain TX/12, using both definitions of seroprotection described above 
(≥40 or ≥110). Following vaccination with SW/13, 52% (15 of 29) of participants with 
baseline TX/12 HI titer <40 were considered seroprotected with TX/12 HI titers ≥40 and 
11% (12 of 114) of participants with baseline TX/12 HI titer <110 were considered 
seroprotected with TX/12 HI titers ≥110. Baseline titer against TX/12 and response against 
SW/13 were independent predictors of seroprotection against TX/12 using either definition 
of seroprotection (≥40 or ≥110). Even small increases in baseline titer against TX/12 greatly 
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increased participants’ odds of being seroprotected after vaccination: a 2-fold higher 
baseline titer increased the odds of seroprotection by 40.67 (95% CI 3.38 – 302.54) for 
TX/12 HI titer ≥40 or 3.52 (95% CI 1.56 – 10.29) for TX/12 HI titer ≥110 (Table 4). 
Response to the vaccine strain also increased the odds of seroprotection against TX/12: a 2-
fold increase in SW/13 response was associated with 5.9 (95% CI 2.0 – 44.1) times higher 
odds of seroprotection with TX/12 HI titer ≥40 and 2.1 (95% CI 1.4 – 3.4) times higher odds 
of seroprotection with TX/12 HI titer ≥110, adjusting for baseline TX/12 titer (Table 4).
Discussion
Antigenic variants of influenza A(H3N2) viruses emerged in 2014 and were the predominant 
A(H3N2) viruses during the 2014–2015 season in the United States. As a result, A/
Switzerland/9715293/2013 (SW/13; HA genetic group 3C.3a) was chosen as the A(H3N2) 
component of the 2015–16 Northern Hemisphere influenza vaccine due to its availability 
and cross-reactivity with the 3C.2a viruses that circulated during 2014–2015. Vaccination 
with SW/13 boosted HI antibodies against both the TX/12 and VI/11 reference viruses from 
the previous A(H3N2) antigenic cluster. For some subjects, we also noted a very small, but 
statistically significant, increase in antibody titers against WU/95, a virus from a 
substantially earlier antigenic cluster. The biological significance of this small increase is 
unclear; WU/95 circulated before almost all participants were born and we therefore do not 
expect a strong back-boost against this virus. Notably, pre- and post-vaccination titers 
against WU/95 remained below the threshold of seroprotection in all participants even after 
vaccination. However, the magnitude of HI antibody titer changes against the earlier 
A(H3N2) viruses after vaccination (i.e., the back-boost) was small in comparison to the 
response against the vaccine antigen SW/13, even after adjusting for baseline HI titer. When 
the mean fold increase against viruses representing past A(H3N2) antigenic clusters is 
stratified by baseline TX/12 titer it is apparent that the strength of the back-boost is 
independent of baseline TX/12 titer. Only the response to the vaccine strain SW/13 was 
significant in determining the magnitude of back-boost against historical antigenic clusters. 
Overall, these data suggest that children vaccinated with a strain from the novel A(H3N2) 
antigenic cluster received only a small boost to antibodies against previously circulating 
A(H3N2) influenza strains.
The value of a back-boost becomes clear if vaccine compositions were to be antigenically 
updated, while the majority of circulating viruses belong to the “old” antigenic cluster. 
Currently, strain changes are only made when evidence suggests that a novel antigenic strain 
is likely to become the dominant strain in circulation, and a suitable candidate vaccine virus 
is available. However, independent lines of emerging evidence may argue in favor of more 
frequent updates. First, repeated vaccination with antigenically similar viruses may 
contribute to reduced vaccine effectiveness [21,22]. The back-boost effect could allow for 
more frequent updates—newly emerging strains could be selected for vaccine formulations 
even before they reach a majority of circulating viruses. In this case there would be a need to 
rely on the vaccine to provide protection against the previous antigenic cluster via the back-
boost. We therefore asked whether vaccination with SW/13 provided a back-boost that 
converted participants’ HI titers against viruses from recently circulating antigenic clusters 
to seroprotective levels, defined both by the standard 40 measure and the more stringent 
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level of 110, which may be more relevant for children. Approximately half the participants 
(15 of 29; 52%) with a baseline HI titer <40 against TX/12, representing the previous 
antigenic cluster, had titers ≥40 against that virus after vaccination. When using the more 
conservative 110 cutoff this proportion dropped to only 11% 12 of 114). Altogether, our data 
suggest that influenza vaccination provides a modest back-boost in children that may not be 
sufficient to provide protection against previous antigenic clusters.
Our study was limited both in the number of participants and the number of virus strains 
examined. Using additional virus strains would allow for a more complete understanding of 
the dynamics of the response against past antigenic clusters. Our study was designed to 
determine whether vaccination with a newly updated vaccine strain was capable of boosting 
responses against recently circulating, “antigenically adjacent” influenza strains. We focused 
on A(H3N2) due to the recent emergence of a novel antigenic cluster, but back-boost effects 
could be different for H1N1 viruses. There were also limitations in the determination of 
influenza infection status. It is possible some participants were sub-clinically exposed or had 
undocumented infection, leading to differences in exposure status and HI antibody titer. 
Undocumented exposures and infection would also explain the lack of effect that infection 
status had in our model. The ability to mount a back-boost response to a given influenza 
virus may be impacted by multiple factors, including the nature of one’s first exposure to 
influenza. It is possible, for example, that the antibody repertoire stimulated by a first 
exposure to multivalent vaccine is fundamentally different from one stimulated by a first 
exposure via infection with a single live virus. We could not determine unambiguously 
whether all individuals in our cohort were first exposed to influenza by vaccination or 
infection, so future detailed studies will be necessary to explore this question. It is also 
worth noting that the HI assay is an indirect measure of neutralization; neutralization assays 
may more sensitively detect back-boosted responses and may also be more relevant to 
protection. However, few studies have sought to correlate antibody responses measured by 
neutralization assay with protection, due in part to the relatively higher cost and complexity 
of neutralization assays [23]. Interestingly, a recent study using neutralization assays 
detected a modest “forward-boost” in children: 38–45% of participants receiving IIV 
containing TX/12 seroconverted to 3C.2a or 3C.3a viruses, respectively [24].
In this study we observed a small but statistically significant boost to antibodies against 
viruses from earlier antigenic clusters in children. One potential factor that could affect the 
back-boost response is immune imprinting. If the participants initial exposure was to an H3, 
the participant may see a larger back-boost than if their initial exposure was to an H1 
[25,26]. Future studies with larger panels of viruses are needed to address this important 
possibility. Additionally, the immunological mechanism of the back-boost should be 
investigated further given the recommendations for annual vaccination. The back-boost 
likely reflects the activation and expansion of strain-specific memory B cells and/or the 
expansion of B cell clones that cross-react to both strains. The effects of repeated 
vaccination on back-boost response are not known and merit further research. Overall, 
understanding the interactions between pre-existing immune responses and vaccination will 
improve influenza vaccine design and efficacy.
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Figure 1. 
Pre- and post-vaccination HI antibody titers in participants with high ≥ 40 vs. low <40 
baseline A/Texas/50/2012 titers. HI antibody responses were measured against 4 antigens, 
pre- and post-vaccination. Subjects were stratified into 2 groups based on their baseline 
response to A/Texas/50/2012. A) Subjects with an A/Texas/50/2012 baseline HI titer <40. B) 
Subjects with an A/Texas/50/2012 baseline HI titer ≥40. Bars and error bars represent mean 
and 95% confidence interval respectively. The horizontal dashed line indicates a 
seroprotective titer of 40. Statistical significance determined using ANOVA with 
Bonferroni’s correction for multiple comparisons.
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Figure 2. 
Estimated post vaccination GMT by increase in A/Switzerland/9715293/2013 titer following 
vaccination with A/Switzerland/9715293/2013. Post-vaccination HI titer against A/Texas/
50/2012, A/Victoria/361/2011, and A/Wuhan/359/1995 were determined using multiple 
linear regression with the baseline GMT for each antigen (43, 28, and 16), respectively. 
Solid line indicates post-vaccination GMT while dotted line indicates the 95% confidence 
interval. The horizontal dashed line indicates a seroprotective titer of 40.
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Table 1
Characteristics of study population by baseline HI titer against A/Texas/50/2012 (2014–2015 vaccine strain)
baseline HI titer against
A/Texas/50/2012
low
HI titer < 40
(n = 29)
high
HI titer ≥ 40
(n = 95) P valuea
all
(n = 124)
Age
  Mean ± Std. Dev. 11.93 ± 3.35 11.98 ± 2.81 0.9 11.97 ± 2.93
No. (%) No. (%) No. (%)
  5–11 years 11 (38) 44 (46) 0.6 55 (44)
  12–17 years 18 (62) 51 (54) 69 (56)
Sex No. (%) No. (%) 0.9 No. (%)
  Male 17 (59) 53 (56) 70 (56)
  Female 12 (41) 42 (44) 54 (44)
High-risk condition b 10 (34) 21 (22) 0.3 31 (24)
2014–2015 vaccination status No. (%) No. (%) 0.6 No. (%)
  unvaccinated 10 (34) 24 (25) 34 (27)
  vaccinated – IIV 17 (59) 60 (63) 77 (62)
  vaccinated – LAIV 2 (7) 11 (12) 13 (11)
PCR confirmed A(H3N2) infection No. (%) No. (%) No. (%)
  2012–2013 1 (3) 9 (9) 0.5 10 (8)
  2014–2015 2 (7) 20 (21) 0.1 22 (18)
Baseline A/Switzerland/9715293/2013 titer, GMT (95% CI) 18 (14 – 24) 68 (56 – 83) <0.001 50 (42 – 61)
Baseline A/Victoria/361/2011 titer, GMT (95% CI) 12 (10 – 15) 36 (31 – 42) <0.001 28 (24 – 32)
Baseline A/Wuhan/359/1995 titer, GMT (95% CI) 9 (6 – 13) 18 (15 – 22) 0.004 16 (13 – 19)
Baseline titer in subjects with PCR confirmed A(H3N2) infection in 2012–2013 (n = 10)
  A/Switzerland/9715293/2013 GMT (95%CI) 75 (36 – 153)
  A/Texas/50/2012 GMT (95% CI) 49 (35 – 70)
  A/Victoria/361/2011 GMT (95% CI) 30 (20 – 46)
  A/Wuhan/359/1995 GMT (95% CI) 10 (6 – 17)
Baseline titer in subjects with PCR confirmed A(H3N2) infection in 2014–2015 (n = 22)
  A/Switzerland/9715293/2013 GMT (95%CI) 60 (44 – 83)
  A/Texas/50/2012 GMT (95% CI) 55 (42 – 71)
  A/Victoria/361/2011 GMT (95% CI) 33 (25 – 43)
  A/Wuhan/359/1995 GMT (95% CI) 15 (11 – 20)
Abbreviations: IIV = Inactivated Influenza Vaccine, LAIV = Live Attenuated Influenza Vaccine, GMT – Geometric Mean Titer
aStatistical significance calculated with Chi-Square, T-test (log transformed for GMT), or Fishers exact test, P values were adjusted using 
Bonferroni’s method of adjusting for multiple comparisons.
b
Presence of ≥1 medical record–documented high-risk code as defined by the Advisory Committee on Immunization Practices guidance for 
conditions that increase risk for complications from influenza [16,17].
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Table 3
Factors associated with post-vaccination HI titers against viruses representing past A(H3N2) antigenic clusters 
in linear regression models.
Factors Fold increase in
post-vaccination HI
titer
95% CI P value
A/Texas/50/2012
  A 2-fold increase in A/Switzerland/9715293/2013 responsea 1.19 1.13 – 1.25 < 0.0001
  A 2-fold increase in baseline A/Texas/50/2012 HI titer 1.73 1.62 – 1.84 < 0.0001
A/Victoria/361/2011
  A 2-fold increase in A/Switzerland/9715293/2013 responsea 1.14 1.07 – 1.21 < 0.0001
  A 2-fold increase in baseline A/Victoria/361/2011 HI titer 1.81 1.70 – 1.93 < 0.0001
A/Wuhan/359/1995
  A 2-fold increase in A/Switzerland/9715293/2013 responsea 1.11 1.05 – 1.17 0.0004
  A 2-fold increase in baseline A/Wuhan/359/1995 HI titer 1.90 1.80 – 2.00 < 0.0001
aA/Switzerland/9715293/2013 response defined as post-vaccination titer/pre-vaccination titer
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Table 4
Factors associated with post-vaccination seroprotection (HI titer ≥ 40 or HI titer ≥ 110) against A/Texas/
50/2012 in multiple logistic regression models.
Factors OR 95% CI P value
Seroprotection with TX/12 titer ≥ 40 (n = 29)a
  A 2-fold increase in A/Switzerland/9715293/2013 responseb 5.92 2.01 – 44.08 0.0128
  A 2-fold increase in baseline A/Texas/50/2012 titer 40.67 3.38 – 302.54 0.0223
Seroprotection with TX/12 titer ≥ 110 (n = 114)a
  A 2-fold increase in A/Switzerland/9715293/2013 responseb 2.08 1.41 – 3.36 0.0008
  A 2-fold increase in baseline A/Texas/50/2012 titer 3.52 1.56 – 10.29 0.0082
aparticipants with baseline titers above the seroprotective level were excluded
bA/Switzerland/9715293/2013 response defined as post-vaccination titer/pre-vaccination titer
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